About Valinor Pharma
Valinor Pharma is a Healthcare company based in Chicago (United States) founded in 2021, and was acquired by Gruenenthal Group in July 2024. A medicine for pain management is developed by the company. Its chief executive, as recorded, is Todd N Smith. Valinor Pharma offers products and services including MOVANTIK. Its focus areas include Life Sciences, Pain Management, Drugs and Diversified. Its legal entity is Valinor Pharma, LLC. Its competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Valinor Pharma was founded in 2021 and is based in Chicago, United States. Operations center on the pharmaceutical sector, with focus placed on developing treatments for pain-related conditions. MOVANTIK, a Naloxegol Oxalate gel, is provided as a solution for opioid-induced constipation among adult patients with chronic non-cancer pain. Leadership is headed by CEO Todd N Smith.
- Headquarters Chicago, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website valinorrx.com
- Social LinkedIn
- Acquired by Gruenenthal Group (Jul 2024)
- Legal Name Valinor Pharma, Llc
- Investors
- Acquired byGruenenthal Group
(Jul 2024)
Products & Services of Valinor Pharma
Valinor Pharma offers a comprehensive portfolio of products and services, including MOVANTIK.
Treats opioid-induced constipation for patient needs effectively.
Investors in Valinor Pharma
Valinor Pharma has secured backing from 1 investor. Prominent investors backing the company include Gruenenthal Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Specialty biopharmaceutical products are developed internationally by Gruenenthal Group. | 1946 | grunenthal.com | Aachen, Germany |
Investor details for Valinor Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Valinor Pharma
3 people are tracked at Valinor Pharma (2 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Todd N Smith | CEO | Leadership |
Ron C. | Vice President Of Manufacturing & Supply Chain | Leadership |
Clifton Owen | Territory Manager - Medical Sales Executive | Team |
Complete people profiles for Valinor Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Valinor Pharma
2 dated milestones of Valinor Pharma across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Valinor Pharma is founded.
- Exit Acquired by Gruenenthal Group.
Competitors of Valinor Pharma
Valinor Pharma has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. |
Detailed competitors of Valinor Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pain Management
3 companies that operate in the same segment as Valinor Pharma (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Valinor Pharma
Complete news archive for Valinor Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Valinor Pharma
Valinor Pharma was founded in 2021.
Valinor Pharma is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Todd N Smith is the CEO of Valinor Pharma, as recorded in our data.
Valinor Pharma was founded in 2021 and is based in Chicago, United States. Operations center on the pharmaceutical sector, with focus placed on developing treatments for pain-related conditions. MOVANTIK, a Naloxegol Oxalate gel, is provided as a solution for opioid-induced constipation among adult patients with chronic non-cancer pain. Leadership is headed by CEO Todd N Smith.
Valinor Pharma's top competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
Valinor Pharma offers MOVANTIK.
Valinor Pharma has 1 investor. Key investors include Gruenenthal Group.
Valinor Pharma operates through Valinor Pharma, Llc.
Yes. Valinor Pharma was acquired by Gruenenthal Group in July 2024.